DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
UBP145 (HB4717)
Description:Selective antagonist for GluN2D subunit containing NMDA receptors
Purity:>97%
-
-
UBP 302 (HB0627)
Description:Potent, selective GluK1 subunit selective kainate receptor antagonist
Purity:>98%
-
UBP 310 (HB0628)
Description:Potent, selective GluK1 / GluK3 subunit selective kainate receptor antagonist
Purity:>98%
-
-
UBP709 (HB9204)
Description:NMDAR pan-PAM that potentiates all GluN2 subunits. Enhances LTD and decreases LTP.Â
Purity:>98%
-
UBP714 ammonium salt (HB8161)
Description:NMDAR PAM which potentiates GluN2A and GluN2B with minimal effects on 2C and 2D.
Purity:>98%
-
UCPH 101 (HB0630)
Description:UCPH-101 is a potent, selective, non-competitive EAAT1 inhibitor
Purity:>98%
-
